Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$107.59

0.27 (0.25%)

06:09
10/02/18
10/02
06:09
10/02/18
06:09

Eli Lilly's PRONTO-T1D, PRONTO-T2D meet primary efficacy endpoint

Readouts from two phase 3 clinical trials demonstrated that Eli Lilly's Ultra Rapid Lispro, or URLi, met the primary efficacy endpoint of non-inferior A1C reduction from baseline compared to Humalog and also demonstrated significantly improved post-meal glucose control in people with type 1 and type 2 diabetes. URLi is Lilly's novel mealtime insulin formulation that was developed to help better control blood glucose levels after meals by more closely mirroring the way insulin works in people without diabetes. The two phase 3 studies, PRONTO-T1D and PRONTO-T2D, evaluated the safety and efficacy of URLi compared to Humalog in people with type 1 and type 2 diabetes, respectively. The primary efficacy endpoint of non-inferiority to Humalog, as measured by A1C reduction from baseline, was met in both studies at 26 weeks. In both populations, URLi demonstrated superior reduction in glucose excursions at both one and two hours during a meal test. The studies showed no significant difference in severe, nocturnal or overall hypoglycemia rates reported by study participants.

  • 04

    Oct

LLY Eli Lilly
$107.59

0.27 (0.25%)

09/27/18
CANT
09/27/18
NO CHANGE
Target $25
CANT
Neutral
Teva recent weakness may be related to CGRP worries, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen said she has received a meaningful number of incoming questions about Teva's recent share weakness, noting that the company confirmed it is aware of no new news driving the pullback. Her discussions lead her to believe that some investors have read Teva's comments to mean that there could be higher than expected spending on its calcitonin gene-related peptide migraine treatments franchise. Chen also noted that Eli Lilly's (LLY) expected CGRP approval would make the third drug in the class that is approved. Chen also said that some of Teva's competitors have a pricing arbitrage as it relates to CGRP, though she does not see this as an issue based on her diligence. She maintains a Neutral rating on Teva with a $25 price target.
09/28/18
WELS
09/28/18
NO CHANGE
WELS
Market Perform
Lilly's migraine treatment approval adds to Teva worries, says Wells Fargo
Wells Fargo analyst David Maris noted that Eli Lilly (LLY) received FDA approval of Emgality for the prevention of migraines and announced a U.S. list price of $6,900 annually, which is in line with Teva's (TEVA) Ajovy and Aimovig from Amgen (AMGN) and Novartis (NVS). Lilly's approval adds to Teva investor worries, said Maris, who sees migraines being a competitive market with similar drugs "where the competitors are marketing powerhouses...and Teva is undergoing a lot of organizational change." He maintains a Market Perform rating on Teva shares.
10/01/18
GSCO
10/01/18
UPGRADE
Target $30
GSCO
Conviction Buy
Teva upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Jami Rubin added Teva Pharmaceuticals (TEVA) to Goldman's Conviction List with a Buy rating. The analyst calls the recent selloff in the shares a "head scratcher" and sees a buying opportunity at current levels. Recent concerns raised in the marketplace regarding second half of 2018 headwinds and Eli Lilly's (LLY) galcenuzemab approval were already expected and well understood, Rubin tells investors in a research note. The analyst sees "meaningful upside" in shares of Teva and has a $30 price target for the name.
10/01/18
RHCO
10/01/18
NO CHANGE
Target $123
RHCO
Buy
Eli Lilly price target raised to $123 from $105 at SunTrust
SunTrust analyst John Boris raised his price target on Eli Lilly to $123 after meeting with its management and investors, saying the discussions highlighted the company's "solid execution" and diversified volume-driven pipeline growth. The analyst cites the company's "new indications or line extension" - NILEX - opportunities, pointing to diabetes gains from Trulicity, immunology label expansion for Taltz, and another leg of growth in its pain drugs. Boris keeps his Buy rating on Eli Lilly and believes that it is "positioned to drive earnings growth faster than sales, as gross margin and fixed cost leverage yield operating margin expansion".

TODAY'S FREE FLY STORIES

F

Ford

$8.34

-0.17 (-2.00%)

18:08
01/23/19
01/23
18:08
01/23/19
18:08
Hot Stocks
Ford says Russian alliance 'under review' »

Says won't have to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

F

Ford

$8.34

-0.17 (-2.00%)

18:04
01/23/19
01/23
18:04
01/23/19
18:04
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford says 'not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

CHMG

Chemung Financial

$41.99

-0.11 (-0.26%)

18:04
01/23/19
01/23
18:04
01/23/19
18:04
Earnings
Chemung Financial reports Q4 EPS $1.18, consensus $1.04 »

Reports Q4 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$8.34

-0.17 (-2.00%)

18:03
01/23/19
01/23
18:03
01/23/19
18:03
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford says 2019 will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

F

Ford

$8.34

-0.17 (-2.00%)

18:01
01/23/19
01/23
18:01
01/23/19
18:01
Hot Stocks
Ford says 2018 auto EBIT benefited from improvement of market factors »

Says auto EBIT in 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

HSIC

Henry Schein

$76.92

-0.45 (-0.58%)

17:56
01/23/19
01/23
17:56
01/23/19
17:56
Hot Stocks
Henry Schein falls after saying it will not be key supplier to VCA,Pet Partners »

Shares of Henry Schein…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSIC

Henry Schein

$76.92

-0.45 (-0.58%)

17:51
01/23/19
01/23
17:51
01/23/19
17:51
Hot Stocks
Henry Schein will no longer be key supplier to VCA and Pet Partners »

Mars, Incorporated has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLX

Hologic

$44.40

0.22 (0.50%)

17:50
01/23/19
01/23
17:50
01/23/19
17:50
Hot Stocks
Hologic says FDA grants clearance for Aptima Mycoplasma genitalium assay »

Hologic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

F

Ford

$8.34

-0.17 (-2.00%)

17:41
01/23/19
01/23
17:41
01/23/19
17:41
Hot Stocks
Ford says 'optimistic' entering 2019 »

Says 2018 was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

RFL

Rafael Holdings

$16.90

-1.55 (-8.40%)

17:37
01/23/19
01/23
17:37
01/23/19
17:37
Hot Stocks
Rafael Holdings acquires majority stake in Rafael Pharma »

Rafael Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRDA

Crawford & Co.

$0.00

(0.00%)

, CRDB

Crawford & Company

$0.00

(0.00%)

17:34
01/23/19
01/23
17:34
01/23/19
17:34
Hot Stocks
Crawford & Co. to repurchase approximately 1.8M shares of CRD-A and CRD-B »

Crawford & Compan…

CRDA

Crawford & Co.

$0.00

(0.00%)

CRDB

Crawford & Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$31.93

0.13 (0.41%)

17:32
01/23/19
01/23
17:32
01/23/19
17:32
Hot Stocks
Teradyne up 6.5% after Q4 earnings beat, Q1 guidance, stock buyback »

Shares of Teradyne rose…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 28

    May

FHN

First Horizon

$14.59

0.07 (0.48%)

17:29
01/23/19
01/23
17:29
01/23/19
17:29
Syndicate
Breaking Syndicate news story on First Horizon »

First Horizon files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$8.34

-0.17 (-2.00%)

17:28
01/23/19
01/23
17:28
01/23/19
17:28
Hot Stocks
Ford sees longer-term revenue growth exceeding global GDP »

Sees longer-term adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

BA

Boeing

$358.81

0.9 (0.25%)

17:27
01/23/19
01/23
17:27
01/23/19
17:27
Periodicals
Boeing warns that shutdown will eventually impact business, CNBC reports »

According to a CNBC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 28

    May

INBK

First Internet Bancorp

$24.22

-0.23 (-0.94%)

17:23
01/23/19
01/23
17:23
01/23/19
17:23
Earnings
First Internet Bancorp reports Q4 adj. EPS 53c, consensus 60c »

Reports Q4 CET1 capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

INCY

Incyte

$75.20

-2.11 (-2.73%)

17:19
01/23/19
01/23
17:19
01/23/19
17:19
Upgrade
Incyte rating change  »

Incyte upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

HOMB

Home Bancshares

$18.39

0.15 (0.82%)

17:16
01/23/19
01/23
17:16
01/23/19
17:16
Hot Stocks
Home Bancshares raises quarterly dividend 9.1% to 12c per share »

Home BancShares, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

CVBF

CVB Financial

$22.08

-0.01 (-0.05%)

17:15
01/23/19
01/23
17:15
01/23/19
17:15
Earnings
CVB Financial reports Q4 EPS 31c, consensus 34c »

Reports Q4 NII $113.0M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

QSR

Restaurant Brands

$62.61

5.62 (9.86%)

17:15
01/23/19
01/23
17:15
01/23/19
17:15
Upgrade
Restaurant Brands rating change  »

Restaurant Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SPY

SPDR S&P 500 ETF Trust

$263.42

0.37 (0.14%)

, SPX

S&P 500

$0.00

(0.00%)

17:15
01/23/19
01/23
17:15
01/23/19
17:15
Periodicals
White House inquires about at-risk programs from shutdown, Wasington Post says »

Mick Mulvaney, the White…

SPY

SPDR S&P 500 ETF Trust

$263.42

0.37 (0.14%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSB

Franklin Financial Network

$27.73

-0.32 (-1.14%)

17:11
01/23/19
01/23
17:11
01/23/19
17:11
Earnings
Franklin Financial Network reports Q4 core EPS 61c, consensus 62c »

Net interest margin for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 11

    Feb

  • 12

    Feb

  • 13

    Feb

TER

Teradyne

$31.93

0.13 (0.41%)

17:09
01/23/19
01/23
17:09
01/23/19
17:09
Hot Stocks
Breaking Hot Stocks news story on Teradyne »

Teradyne expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 28

    May

TER

Teradyne

$31.93

0.13 (0.41%)

17:08
01/23/19
01/23
17:08
01/23/19
17:08
Earnings
Teradyne sees Q1 EPS 39c-47c, consensus 46c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 28

    May

TER

Teradyne

$31.93

0.13 (0.41%)

17:07
01/23/19
01/23
17:07
01/23/19
17:07
Earnings
Teradyne reports Q4 EPS 63c, consensus 50c »

Reports Q4 revenue $520M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.